# CJC-1295 Dosage in the Research: Doses, Routes, and Half-Life from the Studies

> CJC-1295 human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms/kg. A research-context readout of the CJC-1295 dosage record — no human-use protocol.

This panel reports the doses used in studies. CJC-1295 has no approved human dose; nothing here is a protocol or a recommendation.

## Doses used in the published research

CJC-1295 dosage in the controlled human record is narrow. The pharmacokinetic studies administered single subcutaneous doses of 30, 60, or 90 micrograms per kilogram of body weight in healthy volunteers [1][3]. There is no approved human dose, no titration schedule, and no maintenance regimen in the peer-reviewed literature — the human work was designed to characterize GH and IGF-1 kinetics, not to establish a therapeutic dose.

In animal work, the GHRH-knockout-mouse growth study used a fixed 2-microgram dose per administration at 24-, 48-, or 72-hour intervals [4]. The microgram-per-kilogram human doses and the fixed microgram mouse doses are the only dosing figures grounded in published studies.

The fixed-dose figures circulating in community and clinic "protocols" — commonly cited in the 100-to-300-microgram range for no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin pairings — are not derived from controlled human trials [8]. This site logs what the studies used; it does not convert that into a use instruction.

## Route and half-life

Subcutaneous injection was the primary route in the published research; early GRF(1-29) pharmacokinetic work also used intravenous administration [1][2]. Oral bioavailability is negligible because CJC-1295 is a peptide, so the oral route does not appear in the dosing record.

Half-life is where the two variants diverge most sharply. The DAC variant's half-life was estimated at 5.8 to 8.1 days in healthy adults, with IGF-1 elevation persisting up to 28 days after multiple doses [1]. The no-DAC form, Modified GRF (1-29), is short-acting — minutes to hours — because it lacks the albumin-binding handle and clears at roughly the rate of native GHRH(1-29) with protease-resistant substitutions [1][11]. A dose figure means very different things depending on which variant it describes, which is why the [DAC vs no-DAC](/dac-vs-no-dac) distinction matters before any dosing number does.

## Research handling and stability

In laboratory handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [8]. The four amino-acid substitutions confer resistance to DPP-IV and other proteases, and in the DAC variant the albumin conjugation is what confers the multi-day duration of action [1][2]. These notes describe how the research material is stored and prepared in a laboratory context; they are not preparation instructions for use.

The distinction between a handling description and a use protocol is the line this page holds. CJC-1295 is an unapproved research chemical; the published record characterizes its pharmacokinetics, not a safe human regimen.

---

An instrument-cluster reading of the CJC-1295 record — the established pharmacokinetics lit in cyan, the unapproved status and missing human data flagged in amber and red, with no clinic behind the console and nothing here prescribed or sold.